Contents
Edit links
Tools
Actions
General
- What links here
- Related changes
- Upload file
- Special pages
- Permanent link
- Page information
- Cite this page
- Get shortened URL
- Download QR code
- Wikidata item
Print/export
- Download as PDF
- Printable version
Chemical compound
Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L.[1]
References
- ^ Seekamp A, van Griensven M, Dhondt E, Diefenbeck M, Demeyer I, Vundelinckx G, et al. (October 2004). "The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial". Critical Care Medicine. 32 (10): 2021–8. doi:10.1097/01.CCM.0000142396.59236.F3. PMID 15483410. S2CID 21172224.
Intracellular (initiation) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|